National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

NCCN Flash Update sent April 26, 2013

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Testicular Cancer. These NCCN Guidelines® are currently available as Version 1.2013.

  • Nonseminoma

    • Primary treatment (TEST-11)
      • For Stages IS, IIA S1, IIB S1, IIC, IIIA, IIIB, and IIIC, chemotherapy (with EP, BEP, or VIP) was clarified as a category 1 recommendation.
    • Post-chemotherapy management (TEST-11)
      • For a complete response with negative markers, Stage IS was separated from Stages IIA S1, IIB S1, IIC, and IIIA to indicate that surveillance is the management option for Stage IS.
      • For a partial response with residual embryonal, yolk sac, choriocarcinoma, or seminoma elements remaining, chemotherapy with EP was clarified as a category 1 recommendation.
    • Principles of radiotherapy (TEST-A 3 of 5)
      • For Stage IIA-B, a new bullet was added: "Patients should not receive primary RT if they have a horseshoe (pelvic) kidney, inflammatory bowel disease, or a history of RT."

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®,and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.com.

Free NCCN Guidelines mobile apps for iPad and Android are now available! Visit NCCN.org/apps